Mirum Pharmaceuticals (NASDAQ:MIRM) CFO Sells $469,100.00 in Stock

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) CFO Eric Bjerkholt sold 5,000 shares of the business’s stock in a transaction that occurred on Monday, June 8th. The shares were sold at an average price of $93.82, for a total value of $469,100.00. Following the completion of the transaction, the chief financial officer owned 44,788 shares of the company’s stock, valued at $4,202,010.16. This represents a 10.04% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Eric Bjerkholt also recently made the following trade(s):

• On Monday, March 16th, Eric Bjerkholt sold 7,287 shares of Mirum Pharmaceuticals stock. The shares were sold at an average price of $91.98, for a total value of $670,258.26.

Mirum Pharmaceuticals Price Performance

Shares of MIRM opened at $99.54 on Friday. The company has a debt-to-equity ratio of 1.28, a quick ratio of 1.99 and a current ratio of 2.09. The stock has a 50 day simple moving average of $97.79 and a 200 day simple moving average of $91.08. Mirum Pharmaceuticals, Inc. has a 52-week low of $47.79 and a 52-week high of $114.99. The firm has a market capitalization of $6.07 billion, a PE ratio of -7.31 and a beta of 0.50.

Mirum Pharmaceuticals (NASDAQ:MIRM) last issued its quarterly earnings data on Wednesday, May 6th. The company reported ($13.43) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.75) by ($12.68). Mirum Pharmaceuticals had a negative net margin of 140.24% and a negative return on equity of 11.28%. The business had revenue of $159.88 million during the quarter, compared to analyst estimates of $148.21 million. During the same quarter in the prior year, the firm posted ($0.30) earnings per share. Mirum Pharmaceuticals’s revenue for the quarter was up 43.3% compared to the same quarter last year. Sell-side analysts predict that Mirum Pharmaceuticals, Inc. will post -2.01 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on MIRM. Robert W. Baird boosted their price objective on Mirum Pharmaceuticals from $112.00 to $129.00 and gave the company an “outperform” rating in a research report on Thursday, May 7th. Raymond James Financial reiterated a “strong-buy” rating and issued a $165.00 price objective on shares of Mirum Pharmaceuticals in a research report on Thursday, May 7th. Leerink Partners decreased their price objective on Mirum Pharmaceuticals from $120.00 to $118.00 and set an “outperform” rating for the company in a research report on Thursday, February 26th. Morgan Stanley boosted their price objective on Mirum Pharmaceuticals from $140.00 to $150.00 and gave the company an “overweight” rating in a research report on Thursday. Finally, TD Cowen boosted their target price on Mirum Pharmaceuticals from $125.00 to $145.00 and gave the company a “buy” rating in a research note on Thursday, May 7th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $138.36.

Institutional Investors Weigh In On Mirum Pharmaceuticals

Several institutional investors have recently bought and sold shares of MIRM. Comerica Bank lifted its stake in Mirum Pharmaceuticals by 45.1% in the 1st quarter. Comerica Bank now owns 895 shares of the company’s stock valued at $40,000 after acquiring an additional 278 shares in the last quarter. AQR Capital Management LLC lifted its stake in Mirum Pharmaceuticals by 307.3% in the 1st quarter. AQR Capital Management LLC now owns 49,076 shares of the company’s stock valued at $2,211,000 after acquiring an additional 37,028 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in Mirum Pharmaceuticals by 7.1% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 26,047 shares of the company’s stock valued at $1,176,000 after acquiring an additional 1,720 shares in the last quarter. Caxton Associates LLP bought a new stake in Mirum Pharmaceuticals in the 1st quarter valued at approximately $217,000. Finally, Empowered Funds LLC lifted its stake in Mirum Pharmaceuticals by 15.4% in the 1st quarter. Empowered Funds LLC now owns 38,386 shares of the company’s stock valued at $1,729,000 after acquiring an additional 5,120 shares in the last quarter.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.